Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PGK1 | P00558 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157398 | 0.85 | C5AR1 (0.47) | ALDH1A1CYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL1157252 | 0.83 | L3MBTL1 (0.53) | ALOX15ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL1157410 | 0.81 | C5AR1 (0.46) | ALDH1A1NPC1RAB9AMAPTC5AR1 | |
| SCHEMBL1157896 | 0.79 | MRGPRX1 (0.47) | NPC1RAB9AC5AR1PDE4APDE4B | |
| SCHEMBL1157214 | 0.75 | ALDH1A1 (0.52) | ALOX15ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL6156497 | 0.74 | ALDH1A1 (0.54) | ALOX15ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL1157338 | 0.74 | ALDH1A1 (0.51) | ALOX15ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5309365 | 0.73 | HIF1A (0.63) | ALDH1A1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL11419578 | 0.71 | HTR1A (0.58) | ALDH1A1GAAL3MBTL1PDE4APDE4B | |
| SCHEMBL1157301 | 0.71 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046146-A9 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A | 2011-02-24 | — | — | US | disclosed |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | SCHUMACHER RICHARD A | 2009-02-19 | — | — | US | disclosed |
| US-7405230-B2 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-7205320-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070078139-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A | 2007-04-05 | — | — | US | disclosed |
| EP-1539697-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | Memory Pharmaceutical Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORP. (US) | 2005-06-02 | — | — | US | disclosed |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A (US) | 2004-11-18 | — | — | US | disclosed |
| US-6699890-B2 | N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES | MEMORY PHARMACEUTICALS CORP. | 2004-03-02 | — | — | US | disclosed |
| WO-2004009552-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-1353907-A2 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-08-07 | — | — | US | disclosed |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002074726-A2 | ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | ALOX15 3670/4885ALDH1A1 148/4885MEN1 3293/4885 |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | ALOX15 3670/4885ALDH1A1 148/4885MEN1 3293/4885 |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | ALOX15 3670/4885ALDH1A1 148/4885MEN1 3293/4885 |
| US-20110046146-A9 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | ALOX15 3589/4885ALDH1A1 192/4885MEN1 3301/4885 |
| US-20070078139-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | ALOX15 3589/4885ALDH1A1 192/4885MEN1 3301/4885 |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | PDE4A, PDE4B, PDE3A | ALOX15 3610/4885ALDH1A1 221/4885MEN1 3363/4885 |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | PDE4A, PDE4B, PDE3A | ALOX15 3610/4885ALDH1A1 221/4885MEN1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.